FIG 6.
Cell toxicity of BCL-XL antagonists on a primary cell latency model and participant-derived ex vivo cells. The percentage of cell numbers in each BCL-XL antagonist treatment compared to no Tx (black) or a combination of bryostatin-1+ BCL-XL antagonist treatment compared to bryostatin-1 (blue). Shown is the cell count percentage mean ± SD from separate HIVEs. Statistical significance was determined by one-way ANOVA. *, P < 0.05; **, P < 0.01; ****, P < 0.0001.